ProteinQure Inc.
$206,800.00 CAD
≈ 3 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2023-2024
- Agreement period
- August 16, 2023 – April 30, 2024
- Reference
- nrc-cnrc:172-2023-2024-Q3-1010963
Published purpose
ProteinQure is going to show the potential of its SORT1 delivery platform by demonstrating the ability to cure Trodelvy/Enhertu resistant Triple Negative Breast Cancer (the most deadly form of breast cancer with no treatments). This IRAP project will involve the design and creation of animal models based on patient samples (PDX) which recapitulate acquired resistance to Trodelvy/Enhertu. While simpler PDX models would be sufficient for regulatory purposes, more advanced models increase the commercial potential and likelihood of success for the SORT1 platform in TNBC.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions